ANI Pharmaceuticals (ANIP) stock drops as its Iluvien implant fails in a clinical trial versus Eylea marketed by Regeneron ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Analysts expect the S&P 500 to rise 7.5% over the next year, according to a recent analysis of stock price targets. Wall ...

Roche Holding AG's H2 2025 earnings show solid growth in pharma revenues but highlight pipeline struggles and U.S. pricing pressures. Click for my RHHBY update.

Regeneron Pharmaceuticals has recently launched a Phase 2 trial, testing the waters with a potential breakthrough in melanoma ...

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...

Shares of Regeneron Pharmaceuticals Inc. REGN slid 1.35% to $564.64 Thursday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.07% to ...

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Shares of Regeneron Pharmaceuticals, Inc. REGN have lost 22.6% year to date against the industry’s growth of 0.6%. The stock ...